Research programme: diabetic nephropathy therapeutics - XORTX PharmaAlternative Names: XRx 221; XRx® 108
Latest Information Update: 19 Apr 2016
At a glance
- Originator XORTX Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic neuropathies
Most Recent Events
- 19 Apr 2016 Preclinical trials in Diabetic neuropathies in Canada (unspecified route) before April 2016
- 15 Oct 2015 XORTX Pharma has patent protection for the use of uric acid lowering agents to treat diabetic nephropathy in USA